share_log

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $163

Benzinga Real-time News ·  Jan 17, 2023 06:07

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $148 to $163.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment